Among NAFLD, patients with NASH had significantly higher levels of alanine transaminase (ALT) [51.1 ± 34.0] and aspartate transaminase (AST) [35.6 ± 25.7] than non-NASH NAFLD patients (n=50), ALT [32.1 ± 18.9, P = .002] and AST [23.7 ± 11.6, P = .003]. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatohepatitis.